Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. In addition, the company develops TNX-102 SL, a cyclobenzaprine HCl sublingual tablet for the treatment of major depressive disorder and acute stress reaction/acute stress disorder; TNX-1300, a double-mutant cocaine esterase for the treatment of cocaine intoxication; TNX-1500, an Fc-modified humanized monoclonal antibody to prevent kidney transplant rejection, as well as to treat autoimmune conditions; TNX-4800, a humanized monoclonal antibody for the seasonal prevention of Lyme disease; and TNX-2900, an intranasal oxytocin potentiated with magnesium for the treatment of Prader-Willi syndrome. Further, it is developing TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, and arginine-vasopressin deficiency; TNX-801, a live horsepox vaccine for the prevention of smallpox and mpox; TNX-4200, a small molecule broad-spectrum antiviral agent targeting CD45 for the treatment or prevention of viral disease; TNX-4900, a highly selective small-molecule Sigma-1 receptor antagonist for neuropathic pain; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; and TNX-1800 and TNX-1850, live modified horsepox vaccines for the prevention of COVID. Tonix Pharmaceuticals Holding Corp. was founded in 2007 and is based in Berkeley Heights, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $13M | $-122M | $-124M | $-103M | -50.6% | 29.8% | -4.6% |
| 2024 | $10M | $-125M | $-130M | $-61M | -93.2% | 29.9% | 11.5% |
| 2023 | $8M | $-114M | $-117M | $-110M | -110.6% | - | 5.8% |
| 2022 | $0M | $-111M | $-110M | $-146M | -53.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 7.77 | 10.09 | 13.11 |
| Operating Revenue | - | 0 | 7.77 | 10.09 | 13.11 |
| Cost Of Revenue | - | 0 | 4.74 | 7.76 | 6.64 |
| Gross Profit | - | 0 | 3.03 | 2.33 | 6.47 |
| Operating Expense | - | 112.09 | 121.41 | 77.48 | 129.16 |
| Research And Development | - | 81.88 | 86.66 | 39.97 | 44.49 |
| Selling General And Administration | - | 30.22 | 34.75 | 40.10 | 87.68 |
| Total Expenses | - | 112.09 | 126.15 | 85.24 | 135.80 |
| Operating Income | - | -112.09 | -118.38 | -75.15 | -122.69 |
| Total Operating Income As Reported | - | -112.09 | -118.38 | -136.70 | -125.70 |
| EBITDA | - | -110.84 | -114.09 | -125.38 | -122.01 |
| Normalized EBITDA | - | -110.84 | -114.09 | -72.57 | -119.92 |
| EBIT | - | -112.09 | -118.38 | -128.80 | -123.93 |
| Interest Income | 0.02 | 1.87 | - | 0.02 | 4.15 |
| Interest Expense | - | - | - | 1.23 | 0.09 |
| Net Interest Income | 0.02 | 1.87 | - | -1.21 | 4.06 |
| Other Non Operating Income Expenses | - | 1.87 | 1.72 | -0.87 | -3.30 |
| Other Income Expense | - | 1.87 | 1.72 | -53.67 | -5.39 |
| Interest Income Non Operating | 0.02 | 1.87 | - | 0.02 | 4.15 |
| Interest Expense Non Operating | - | - | - | 1.23 | 0.09 |
| Net Non Operating Interest Income Expense | 0.02 | 1.87 | - | -1.21 | 4.06 |
| Pretax Income | - | -110.22 | -116.66 | -130.04 | -124.02 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income From Continuing And Discontinued Operation | - | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income From Continuing Operation Net Minority Interest | - | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income | - | -110.22 | -116.66 | -130.04 | -124.02 |
| Net Income Common Stockholders | - | -116.88 | -116.66 | -130.04 | -124.02 |
| Net Income Including Noncontrolling Interests | - | -110.22 | -116.66 | -130.04 | -124.02 |
| Normalized Income | - | -110.22 | -116.66 | -77.23 | -121.93 |
| Diluted NI Availto Com Stockholders | - | -116.88 | -116.66 | -130.04 | -124.02 |
| Basic Average Shares | - | 0 | 0.01 | 0.74 | 8.51 |
| Diluted Average Shares | - | 0 | 0.01 | 0.74 | 8.51 |
| Reconciled Depreciation | - | 1.25 | 4.29 | 3.42 | 1.92 |
| Reconciled Cost Of Revenue | - | 0 | 4.74 | 7.76 | 6.64 |
| Total Unusual Items | - | - | 0 | -52.81 | -2.09 |
| Total Unusual Items Excluding Goodwill | - | - | 0 | -52.81 | -2.09 |
| Preferred Stock Dividends | - | 6.66 | - | - | - |
| Special Income Charges | - | - | 0 | -58.96 | -2.09 |
| Other Special Charges | - | - | - | - | 2.09 |
| Write Off | - | - | 0 | 58.96 | 0 |
| Gain On Sale Of Security | - | - | - | 6.15 | - |
| General And Administrative Expense | 23.47 | 30.22 | 34.75 | - | - |
| Other Gand A | 23.47 | 30.22 | 34.75 | - | - |
| Other Operating Expenses | - | - | - | -2.59 | -3.01 |
| Otherunder Preferred Stock Dividend | 0 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Tonix Pharmaceuticals Holding Corp.this co. | TNXP | $189M | -1.53 | 0.77 | -50.6% | 0.14 |
| Nkarta, Inc. | NKTX | $198M | - | 0.63 | -33.3% | - |
| Anika Therapeutics, Inc. | ANIK | $197M | -18.09 | 1.37 | -7.6% | -31.11 |
| Lucid Diagnostics Inc. | LUCD | $195M | - | 17.79 | -645.1% | - |
| Cartesian Therapeutics, Inc. | RNAC |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| $192M |
| -1.48 |
| -1.52 |
| 103.2% |
| -0.96 |
| KORU Medical Systems, Inc. | KRMD | $190M | -72.09 | 11.15 | -15.5% | -85.47 |
| MediWound Ltd. | MDWD | $186M | -7.78 | 4.26 | -54.7% | -8.81 |
| Stereotaxis, Inc. | STXS | $184M | -8.49 | 13.63 | -160.5% | -8.55 |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Peer Median | - | -8.13 | 2.81 | -34.8% | -8.68 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Jan has averaged the highest return (+34.9%); Sep the lowest (-32.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +10.4%Positive MonthJan 2026: +10.37% | -19.0%Negative MonthFeb 2026: -18.97% | -1.6%Neutral MonthMar 2026: -1.57% | -6.0%Negative MonthApr 2026: -5.96% | -4.6%Negative MonthMay 2026: -4.64% | +3.5%Positive MonthJun 2026: +3.49% | -21.6%Negative MonthJul 2026: -21.55% | +27.2%*Positive MonthAug 2026: +27.17% | — | — | — | — |
| 2025 | +30.3%Positive MonthJan 2025: +30.30% | -81.7%Negative MonthFeb 2025: -81.72% | +127.5%Positive MonthMar 2025: +127.48% | +0.7%Neutral MonthApr 2025: +0.73% | +120.9%Positive MonthMay 2025: +120.88% | -9.6%Negative MonthJun 2025: -9.55% | +4.7%Positive MonthJul 2025: +4.72% | -21.4%Negative MonthAug 2025: -21.36% | -18.5%Negative MonthSep 2025: -18.46% | -22.9%Negative MonthOct 2025: -22.93% | -14.2%Negative MonthNov 2025: -14.23% | -2.2%Negative MonthDec 2025: -2.19% |
| 2024 | -20.0%Negative MonthJan 2024: -20.00% | +18.8%Positive MonthFeb 2024: +18.75% | -50.0%Negative MonthMar 2024: -50.00% | -5.3%Negative MonthApr 2024: -5.26% | -11.1%Negative MonthMay 2024: -11.11% | -86.3%Negative MonthJun 2024: -86.33% | -28.6%Negative MonthJul 2024: -28.57% | -54.0%Negative MonthAug 2024: -54.00% | -34.8%Negative MonthSep 2024: -34.78% | +0.0%Neutral MonthOct 2024: +0.00% | +26.7%Positive MonthNov 2024: +26.67% | +73.7%Positive MonthDec 2024: +73.68% |
| 2023 | +187.2%Positive MonthJan 2023: +187.18% | -37.5%Negative MonthFeb 2023: -37.50% | -15.7%Negative MonthMar 2023: -15.71% | -11.9%Negative MonthApr 2023: -11.86% | -44.9%Negative MonthMay 2023: -44.92% | -11.7%Negative MonthJun 2023: -11.73% | -32.3%Negative MonthJul 2023: -32.28% | -9.3%Negative MonthAug 2023: -9.35% | -43.3%Negative MonthSep 2023: -43.30% | +7.3%Positive MonthOct 2023: +7.27% | -11.9%Negative MonthNov 2023: -11.86% | -23.1%Negative MonthDec 2023: -23.08% |
| 2022 | -33.3%Negative MonthJan 2022: -33.33% | -25.0%Negative MonthFeb 2022: -25.00% | +27.8%Positive MonthMar 2022: +27.78% | -34.8%Negative MonthApr 2022: -34.78% | -49.2%Negative MonthMay 2022: -49.17% | -35.2%Negative MonthJun 2022: -35.25% | +6.3%Positive MonthJul 2022: +6.33% | -39.3%Negative MonthAug 2022: -39.29% | -48.0%Negative MonthSep 2022: -48.04% | -15.1%Negative MonthOct 2022: -15.09% | -13.3%Negative MonthNov 2022: -13.33% | +0.0%Neutral MonthDec 2022: +0.00% |
| 2021 | — | — | — | — | +3.5%Positive MonthMay 2021: +3.51% | -5.9%Negative MonthJun 2021: -5.93% | -35.1%Negative MonthJul 2021: -35.14% | -1.4%Neutral MonthAug 2021: -1.39% | -15.5%Negative MonthSep 2021: -15.49% | -8.3%Negative MonthOct 2021: -8.33% | -14.5%Negative MonthNov 2021: -14.55% | -23.4%Negative MonthDec 2021: -23.40% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
